(iii) Patients with CDM were likely to have anti-NXP2 antibodies and negative myositis-specific autoantibodies, whereas those with CADM were likely to have anti-MDA5 antibodies. The gene discussed is MORC3; the disease is clinically amyopathic dermatomyositis.